Dr. Edward Garon, David Geffen School of Medicine at UCLA,
describes the exciting developments with LDK-378 and potentially
other second generation ALK inhibitors for crizotinib-resistant
ALK-positive advanced NSCLC.
About the Podcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.